CAJ | 학술논문

BRAF V600E是结直肠癌中常见的突变位点，约5％～15％的患者携带此位点的突变。本研究应用直接测序方法检测云南省术后经病理确诊的289例结直肠癌患者的正常和肿瘤组织DNA发生BRAF V600E突变情况，并结合临床资料统计分析BRAF V600E突变型患者与高危临床病理特征和预后之间的关系。结果显示，在云南本地结直肠癌289例患者中有10％携带BRAF V600E的突变，且突变型与高危临床病理特征有关。临床随访266例患者中，BRAF V600E突变型患者中位生存期、1年生存率和无疾病生存率低于野生型患者。提示BRAF V600E突变与结直肠癌患者高危临床病理特征和预后有关，可能作为评价结直肠癌患者预测不良预后的一个潜在的分子标志物。
BRAF V600E시결직장암중상견적돌변위점，약5％～15％적환자휴대차위점적돌변。본연구응용직접측서방법검측운남성술후경병리학진적289례결직장암환자적정상화종류조직DNA발생BRAF V600E돌변정황，병결합림상자료통계분석BRAF V600E돌변형환자여고위림상병리특정화예후지간적관계。결과현시，재운남본지결직장암289례환자중유10％휴대BRAF V600E적돌변，차돌변형여고위림상병리특정유관。림상수방266례환자중，BRAF V600E돌변형환자중위생존기、1년생존솔화무질병생존솔저우야생형환자。제시BRAF V600E돌변여결직장암환자고위림상병리특정화예후유관，가능작위평개결직장암환자예측불량예후적일개잠재적분자표지물。
The BRAF V600E mutation is the most common genetic alteration found in colorectal carcinoma (CRC),accounting for about 5%-15%of colorectal carcinomas.Direct sequencing to detect the BRAF V600E mutation has recently become commercially available.From January 2010 to October 2013,289 colorectal cancer patients who underwent surgery in First Affiliated Hospital of Kunming Medical University Hospital are enrolled in this study to examine BRAF V600E mutation associated with high -risk clinicopathologic Features and survival.As the results show,the BRAF V600E mutation is found in 29/289 (10%)colorectal cancer patients from Yunnan.Compared with BRAF wild-type adenocarcinomas,BRAF-mutated adenocarcinomas frequently demonstrate more adverse histopathologic features.The BRAF V600E mutation is associated with high -risk clinicopathologic features and outcomes in CRC patients from Yunnan,which suggests that the BRAF V600E mutation may be a potential prognostic molecular marker in CRC patients.